Makers Laboratories Shows Positive Growth in Q3

Makers Laboratories, a microcap pharmaceutical company, recently announced its financial results for the quarter ended September 2023. The company's net sales saw a slight increase of 0.20% compared to the previous quarter, while its consolidated net profit showed a significant growth of 36.19%. This is a positive sign for the company, as it had faced a decline of 15.08% in net sales and a loss of 650.00% in net profit in the quarter ended June 2023.

The operating profit (PBDIT) excluding other income also showed a remarkable growth of 195.00% compared to a decline of 111.24% in the previous quarter. However, the company's interest expenses saw a slight increase of 19.51% compared to 64.00% in the previous quarter. Despite this, the operating profit margin (excluding other income) has improved from the previous quarter.

While the financial performance of Makers Laboratories in the quarter ended September 2023 has been negative, it has remained consistent in the last three months. However, there are some areas that need improvement based on the financials. The company's operating cash flow has been the lowest in the last three years, indicating a decline in cash revenues from business operations. Additionally, the company's short-term liquidity has deteriorated, with its cash and cash equivalents being the lowest in the last six half-yearly periods. Moreover, the company has been distributing lower dividends compared to previous years, with the dividend per share (DPS) being the lowest in the last five years. The dividend payout ratio (DPR) has also been the lowest in the last five years, indicating a lower proportion of profits being distributed as dividends.

Overall, while Makers Laboratories has shown some positive growth in its financials for the quarter ended September 2023, there are still some areas that need improvement. Investors should carefully consider these factors before making any investment decisions.